NEW YORK, Dec. 4 – Paradigm Genetics has entered a deal to acquire Celera’s AgGen plant genomics and genotyping business in a stock deal valued at $2.1 million, the companies said Tuesday.

Under the terms of the deal, Celera will receive 422,459 Paradigm shares. Paradigm closed at $4.87 in trading on the Nasdaq Monday.

Celera will also share service revenues with Paradigm. Further details and specifics about the revenue sharing plan were not available.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.